-
Mashup Score: 17Quantifying the Value of Multigene Testing in Resected Early Stage Lung Adenocarcinoma - 11 hour(s) ago
Tyrosine kinase inhibitors and immune checkpoint inhibitors (ICIs), each requiring testing for precision biomarkers, have recently been approved in the adjuvant setting. We assessed the potential value of multigene testing in early lung adenocarcinoma (LUAD).
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 17Quantifying the Value of Multigene Testing in Resected Early Stage Lung Adenocarcinoma - 13 hour(s) ago
Tyrosine kinase inhibitors and immune checkpoint inhibitors (ICIs), each requiring testing for precision biomarkers, have recently been approved in the adjuvant setting. We assessed the potential value of multigene testing in early lung adenocarcinoma (LUAD).
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 9UH operating losses again top $200M; but system says big investment in My Chart is starting to pay off - 13 hour(s) ago
University Hospitals, MetroHealth and Southwest General all reported operating losses in 2023; net income up at Cleveland Clinic
Source: www.cleveland.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 11
Palliative care (PC) plays a critical role in managing the difficulties associated with genitourinary malignancies. Its primary aim is to improve the overall health of patients, provide support to both patients and their caregivers, and help individuals to navigate the complex decisions about treatment and end-of-life care. PC takes a holistic approach to patient care, recognizing that genitourinary malignancies affect multiple aspects of a person’s life. By addressing physical, emotional, social, and spiritual needs, PC aims to provide comprehensive support that is consistent with the patient’s values and preferences. The goal is to optimize comfort, minimize distress, and enhance the patient’s quality of life throughout the course of the illness. PC is not a one-off intervention, but an ongoing source of support. This article aims to provide a thorough overview of the critical elements involved in addressing the challenges posed by genitourinary cancers, emphasizing the importance of
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 17
The origins of cancer vaccines date back to the 1800s. Since then, there have been significant efforts to generate vaccines against solid and hematologic malignancies using a variety of platforms. To date, these efforts have generally been met with minimal success. However, in the era of improved methods and technological advancements, supported by compelling preclinical and clinical data, a wave of renewed interest in the field offers the promise of discovering field-changing paradigms in the management of established and resected disease using cancer vaccines. These include novel approaches to personalized neoantigen vaccine development, as well as innovative immune-modulatory vaccines (IMVs) that facilitate activation of antiregulatory T cells to limit immunosuppression caused by regulatory immune cells. This article will introduce some of the limitations that have affected cancer vaccine development over the past several decades, followed by an introduction to the latest advancemen
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 52
This overview provides a thorough review of current treatment approaches for first-line management of nononcogenic addicted non–small cell lung cancer. We also address pertinent clinical decision-making queries encountered in everyday practice, such as the optimal treatment strategy for PD-L1–high patients, predictive factors for response to immune checkpoint inhibitors (ICI) both in terms of patient and cancer characteristics, the potential benefits of dual checkpoint blockade, and the unresolved issue of safe discontinuation strategies for long-term responders. Around one in five patients falls into this latter category while the majority develop either primary or acquired resistance to ICI-based first-line therapy, necessitating effective subsequent lines of treatment. Docetaxel, with or without combination of antiangiogenic agents, serves as the backbone of treatment, although evidence in the post-ICI setting is limited. Given that an inflamed tumor microenvironment (TME) is crucia
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0F.T.C. Issues Ban on Worker Noncompete Clauses - 10 day(s) ago
The rule would prohibit companies from limiting their employees’ ability to work for rivals, a change that could increase competition and boost wages.
Source: www.nytimes.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0F.T.C. Issues Ban on Worker Noncompete Clauses - 10 day(s) ago
The rule would prohibit companies from limiting their employees’ ability to work for rivals, a change that could increase competition and boost wages.
Source: www.nytimes.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 48New Treatment Options for Patients With Oncogene-Addicted Non–Small Cell Lung Cancer Focusing on EGFR-Mutant Tumors - 1 month(s) ago
Druggable oncogene-driven non–small cell lung cancer has led to innovative systemic treatment options, improving patients’ outcome. This benefit is not only achieved in the metastatic setting but also in the postsurgical setting, such as in lung cancers harboring a common sensitizing EGFR mutation or ALK-rearrangement. To enhance the outcome of these patients, we need to understand the mechanisms of acquired resistance and evaluate the role of new drugs with novel mechanisms of action in the treatment landscape. In this chapter, we review treatment strategies of EGFR-mutant tumors in all stages, the mechanisms of acquired strategies, and novel therapies in this subset.
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 43
Aim: We assessed treatment patterns and outcomes in patients with metastatic nonsquamous non-small-cell lung cancer (mNSCLC) who initiated first-line pembrolizumab–platinum–pemetrexed (induction) in US community oncology settings. Methods: Patients initiating induction were retrospectively identified. Patients continuing pembrolizumab afterward underwent chart review. Clinical outcomes were described by maintenance pemetrexed exposure after inverse probability of treatment weighting (IPTW). Results: Median induction pembrolizumab and pemetrexed durations were 5.1 and 4.2 months. Among patients continuing pembrolizumab after induction, 64% received maintenance pemetrexed. Common discontinuation reasons for induction pemetrexed were completion of planned therapy (79%) and partial response (68%) and progressive disease (38%) and toxicity (29%) for maintenance pemetrexed. After IPTW, median overall survival and real-world progression-free survival were longer in patients continuing pembrol
Source: www.futuremedicine.comCategories: General Medicine News, Hem/OncsTweet
Quantifying the Value of Multigene Testing in Resected Early Stage Lung Adenocarcinoma - Journal of Thoracic Oncology https://t.co/r2s1lblp3n @mtmdphd